The European Medicines Agency said on Friday Eli Lilly's weight-loss drug Mounjaro does not need a separate approval for the ...

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...

Sleep apnea, a widespread health issue, causes breathing interruptions during sleep, leading to oxygen deprivation and ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

In a decision that could streamline treatment options for millions, the European Medicines Agency (EMA) said on Friday that Eli Lilly's 9NYSE:LLY) weight-loss drug Mounjaro wouldn't require separate ...

Revolutionary weight-loss drugs are transforming U.S. health care, prompting patients to seek diagnoses for obesity-related ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

(Reuters) – The European Medicines Agency said on Friday Eli Lilly’s weight-loss drug does not need a separate approval for the treatment of a sleep disorder called obstructive sleep apnea (OSA). The ...

Weight-loss drugs are increasingly prescribed in the U.S., not only for obesity treatment but also to facilitate eligibility ...

Approval for use beyond weight-loss could be a shot in the arm for the companies at a time when demand for the drugs is already surging. Obstructive sleep apnea affects roughly 1 billion people ...